The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan

References

• de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine:clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004;104:857–864.
   PubMed Web of Science ®Google Scholar
• Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002;8:468–476.
   PubMed Web of Science ®Google Scholar
• Russell JA, Savoie ML, Balogh A, et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007;13:814–821.
   PubMed Web of Science ®Google Scholar
• Andersson BS, de Lima M, Thall PF, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008;14:672–684.
   PubMed Web of Science ®Google Scholar
• Pidala J, Kim J, Anasetti C, et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol 2010;3:36–44.
   PubMed Web of Science ®Google Scholar
• Perkins J, Field T, Kim J, et al. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Bone Marrow Transplantation 2011;46:1418–1425.
   PubMed Web of Science ®Google Scholar
• Chae YS, Sohn SK, Kim JG, et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation:comparison with BuCy2. Bone Marrow Transplantation 2007;40:541–547.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167–1173.
   PubMed Web of Science ®Google Scholar
• Faderl S, Ferrajoli A, Wierda W, et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008;113: 2090–2096.
   PubMed Web of Science ®Google Scholar
• Jeha S, Razzouk B, Rytting M, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol 2009;27:4392–4397.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549–555.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Li Y, Murray D, et al. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol 2011;81:222–232.
   PubMed Web of Science ®Google Scholar
• Andersson BS, Valdez BC, de Lima M, et al. Clofarabine + fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011;17:893–900.
   PubMed Web of Science ®Google Scholar
• Ruefli AA, Bernhard D, Tainton KM, et al. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer 2002;99: 292–298.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004; 101:540–545.
   PubMed Web of Science ®Google Scholar
• Shao Y, Gao Z, Marks PA, et al. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004;101:18030–18035.
   PubMed Web of Science ®Google Scholar
• Yu C, Dasmahapatra G, Dent P, et al. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL + human leukemia cells. Leukemia 2005;19:1579–1589.
   PubMed Web of Science ®Google Scholar
• Lindemann RK, Newbold A, Whitecross KF, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007;104:8071–8076.
   PubMed Web of Science ®Google Scholar
• Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007;16:1111–1120.
   PubMed Web of Science ®Google Scholar
• Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat:development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84–90.
   PubMed Web of Science ®Google Scholar
• Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005;2:150–157.
   PubMedGoogle Scholar
• Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102:673–678.
   PubMed Web of Science ®Google Scholar
• Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc) 2007;43:585–599.
   PubMed Web of Science ®Google Scholar
• Lee JH, Choy ML, Ngo L, et al. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 2010;107:14639–14644.
   PubMed Web of Science ®Google Scholar
• Andersson BS, Bergerheim US, Collins VP, et al. KBM-3, an in vitro model of human acute myelomonocytic leukemia. Exp Hematol 1992;20:361–367.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Murray D, Ramdas L, et al. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res 2008;32: 1684–1697.
   PubMed Web of Science ®Google Scholar
• Drexler HG. The leukemia-lymphoma cell line factsbook. San Diego, CA: Academic Press; 2001.
   Google Scholar
• Quentmeier H, Martelli MP, Dirks WG, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005;19:1760–1767.
   PubMed Web of Science ®Google Scholar
• Carter BZ, Mak DH, Schober WD, et al. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 2008;111:3742–3750.
   PubMed Web of Science ®Google Scholar
• Kasugai S, Hasegawa N, Ogura H. A simple in vitro cytotoxicity test using the MTT (3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) colorimetric assay: analysis of eugenol toxicity on dental pulp cells (RPC-C2A). Jpn J Pharmacol 1990;52:95–100.
   PubMedGoogle Scholar
• Salvioli S, Ardizzoni A, Franceschi C, et al. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997;411:77–82.
   PubMed Web of Science ®Google Scholar
• Schottelius A, Brennscheidt U, Ludwig WD, et al. Mechanisms of p53 alteration in acute leukemias. Leukemia 1994;8:1673–1681.
   PubMed Web of Science ®Google Scholar
• Nakano Y, Naoe T, Kiyoi H, et al. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. Eur J Haematol 2000;65:23–31.
   PubMed Web of Science ®Google Scholar
• Rogakou EP, Boon C, Redon C, et al. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999;146:905–916.
   PubMed Web of Science ®Google Scholar
• Vayssiere JL, Petit PX, Risler Y, et al. Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc Natl Acad Sci USA 1994;91:11752–11756.
   PubMed Web of Science ®Google Scholar
• Ankarcrona M, Dypbukt JM, Bonfoco E, et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995;15:961–973.
   PubMed Web of Science ®Google Scholar
• Marchenko ND, Zaika A, Moll UM. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 2000;275:16202–16212.
   PubMed Web of Science ®Google Scholar
• Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003;11:577–590.
   PubMed Web of Science ®Google Scholar
• Erster S, Mihara M, Kim RH, et al. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 2004;24:6728–6741.
   PubMed Web of Science ®Google Scholar
• Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–331.
   PubMed Web of Science ®Google Scholar
• Kojima K, Shimanuki M, Shikami M, et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 2008;22:1728–1736.
   PubMed Web of Science ®Google Scholar
• Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117–129.
   PubMed Web of Science ®Google Scholar
• Irwin MS, Kondo K, Marin MC, et al. Chemosensitivity linked to p73 function. Cancer Cell 2003;3:403–410.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci 2005;96:729–737.
   PubMed Web of Science ®Google Scholar
• Vayssade M, Haddada H, Faridoni-Laurens L, et al. P73 functionally replaces p53 in adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer 2005;116:860–869.
   PubMed Web of Science ®Google Scholar
• Nyman U, Sobczak-Pluta A, Vlachos P, et al. Full-length p73alpha represses drug-induced apoptosis in small cell lung carcinoma cells. J Biol Chem 2005;280:34159–34169.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Murray D, Nieto Y, et al. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. Leuk Lymphoma 2012;53:973–981.
   PubMed Web of Science ®Google Scholar
• Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000;96:3537–3543.
   PubMed Web of Science ®Google Scholar
• Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91:325–334.
   PubMed Web of Science ®Google Scholar
• Evan G, Littlewood T. A matter of life and cell death. Science 1998;281:1317–1322.
   PubMed Web of Science ®Google Scholar
• Genini D, Budihardjo I, Plunkett W, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem 2000;275:29–34.
   PubMed Web of Science ®Google Scholar
• Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 2002;100:1810–1816.
   PubMed Web of Science ®Google Scholar
• Faria JR, Yamamoto M, Faria RM, et al. Fludarabine induces apoptosis in chronic lymphocytic leukemia-the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins. Braz J Med Biol Res 2006;39: 327–333.
   PubMed Web of Science ®Google Scholar
• Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996;93:5705–5708.
   PubMed Web of Science ®Google Scholar
• Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 2009;280:201–210.
   PubMed Web of Science ®Google Scholar
• Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280:125–133.
   PubMed Web of Science ®Google Scholar
• Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet 2007;8: 9–22.
   PubMed Web of Science ®Google Scholar
• Ke XS, Qu Y, Rostad K, et al. Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One 2009; 4:e4687.
   PubMed Web of Science ®Google Scholar
• Vegliante MC, Royo C, Palomero J, et al. Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications. PLoS One 2011;6:e21382.
   Web of Science ®Google Scholar
• Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012;22:180–193.
   PubMed Web of Science ®Google Scholar
• Jost CA, Marin MC, Kaelin WG, Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997;389:191–194.
   PubMed Web of Science ®Google Scholar
• Hainaut P, Soussi T, Shomer B, et al. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 1997;25:151–157.
   PubMed Web of Science ®Google Scholar
• Soenen V, Preudhomme C, Roumier C, et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 1998;91:1008–1015.
   PubMed Web of Science ®Google Scholar